Technology-Assisted Cholesterol Trial in Consumers (TACTiC)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1196 participants.

Also called NCT04964544

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,196 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04964544
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04964544. Allocation not applicable; no masking; primary purpose treatment. Start 2021-07-08 (actual); primary completion 2023-03-01 (actual). Results posted on 2024-10-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Technology-Assisted Cholesterol Trial in Consumers (TACTiC)
Acronym
TACTiC
Condition
High Cholesterol
Intervention (Combination product)
5 mg rosuvastatin calcium with a Web App (combination product)
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Concentrics Research (class: other)
Collaborator
Idea Evolver (class: industry)
Collaborator
The Cleveland Clinic (class: other)

Record details

Record id
cardio:ct-nct04964544
Content hash
5d4582421fab075176cc26118d812e283b552ddf5fa27f25e7c01dfd5bb71495